Join to View Full Profile
1 DNA WaySouth San Francisco, CA 94080
Phone+1 415-846-8056
Dr. McCall is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Bruce McCall is an oncologist based in South San Francisco, CA. He completed a residency in Internal Medicine at St Mary's Hospital and Medical Center from 2001 to 2004 and a residency in Anesthesiology at the University of Washington from 1989 to 1993, after graduating from the University of California San Diego School of Medicine in 1989. His research contributions include multiple publications in high-impact journals, such as an individualized risk mitigation approach for the Mosunetuzumab development program presented at the American Society of Hematology Meeting, and studies on novel therapeutic agents for advanced solid tumors, with several of his works being frequently cited by other publications.
Education & Training
St Mary's Hospital and Medical CenterResidency, Internal Medicine, 2001 - 2004
University of WashingtonResidency, Anesthesiology, 1989 - 1993
University of California San Diego School of MedicineClass of 1989
Certifications & Licensure
American Board of Internal Medicine Internal Medicine
American Board of Anesthesiology Adult Cardiac Anesthesiology
Publications & Presentations
PubMed
- 116 citationsPhase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumorsAsha Nayak-Kapoor, Zhonglin Hao, Ramses F. Sadek, Robin Dobbins, Lisa Marshall
Journal for Immunotherapy of Cancer. 2018-06-20 - 18 citationsPhase I study of the anti-α5β1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumorsColin D. Weekes, Lee S. Rosen, Anna Capasso, Kit Man Wong, Weilan Ye
Cancer Chemotherapy and Pharmacology. 2018-06-15 - 18 citationsRandomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First‐Line Nonsquamous Non‐Small Cel...Joachim von Pawel, David R. Spigel, Thomas Ervin, György Losonczy, Fabrice Barlesi
The Oncologist. 2018-06-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
